Abivax S.A.
ABVX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €11 | €5 | €5 | €0 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €11 | €4 | €5 | -€0 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| R&D Expenses | €147 | €103 | €49 | €47 |
| G&A Expenses | €33 | €28 | €7 | €6 |
| SG&A Expenses | €39 | €29 | €7 | €6 |
| Sales & Mktg Exp. | €6 | €1 | €0 | €0 |
| Other Operating Expenses | -€1 | -€0 | €0 | -€0 |
| Operating Expenses | €184 | €132 | €57 | €52 |
| Operating Income | -€185 | -€127 | -€65 | -€52 |
| % Margin | -1,718.2% | -2,756.5% | -1,414.7% | -141,045.9% |
| Other Income/Exp. Net | €3 | -€25 | -€0 | €7 |
| Pre-Tax Income | -€183 | -€152 | -€65 | -€46 |
| Tax Expense | -€7 | -€4 | -€4 | -€4 |
| Net Income | -€176 | -€148 | -€61 | -€42 |
| % Margin | -1,633.1% | -3,197.1% | -1,325.3% | -114,735.1% |
| EPS | -2.8 | -3.43 | -3.18 | -2.75 |
| % Growth | 18.4% | -7.9% | -15.6% | – |
| EPS Diluted | -2.8 | -3.43 | -3.18 | -2.75 |
| Weighted Avg Shares Out | 63 | 43 | 19 | 15 |
| Weighted Avg Shares Out Dil | 63 | 43 | 19 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | €8 | €1 | €0 | €0 |
| Interest Expense | €14 | €14 | €7 | €4 |
| Depreciation & Amortization | €1 | €1 | €0 | €0 |
| EBITDA | -€168 | -€133 | -€53 | -€42 |
| % Margin | -1,553.8% | -2,882.6% | -1,163.3% | -114,040.5% |